Delivering cargoes into cancer cells using DNA aptamers targeting internalized surface portals

Biochimica et Biophysica Acta - Biomembranes

Volumn 1798, Issue 12, 2010, Pages 2190-2200

  Orava, Erik W ^a,c   Cicmil, Nenad ^b   Gariépy, Jean ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c Institute of Clinical Evaluative Sciences   (Canada)

Author keywords

Antibody; Anticancer agent; Aptamer; Chemotherapy; Drug delivery; Nanomedicine; SELEX

Indexed keywords

A10 (DRUG); ANTISOMA; APTAMER; AS 1411; CARCINOEMBRYONIC ANTIGEN; CD33 ANTIGEN; CISPLATIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DOCETAXEL; DOXORUBICIN; GELONIN; GEMTUZUMAB OZOGAMICIN; LIPOSOME; MUCIN 1; NANOMATERIAL; NANOPARTICLE; OLIGONUCLEOTIDE; PEGAPTANIB; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE 7; QUANTUM DOT; RANIBIZUMAB; SGC8C; SINGLE STRANDED DNA; SINGLE STRANDED RNA; TALAPORFIN; TECHNETIUM 99M; TENASCIN; TRANSFER RNA; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIGEN BINDING; ANTIGEN EXPRESSION; CANCER CELL; CANCER SURVIVAL; CATALYSIS; CELL TRANSPORT; CLINICAL TRIAL; CRYSTAL STRUCTURE; CYTOTOXICITY; DISEASE FREE SURVIVAL; DNA SEQUENCE; DNA STRUCTURE; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; GOLGI COMPLEX; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOGENICITY; INTERNALIZATION; MELANOMA; NONHUMAN; PHAGOCYTOSIS; PINOCYTOSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN TARGETING; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RNA STRUCTURE; SOLID PHASE SYNTHESIS; STATIC ELECTRICITY; TANDEM REPEAT; VIRUS CAPSID;

ANIMALS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; APTAMERS, NUCLEOTIDE; CELL MEMBRANE; DRUG DELIVERY SYSTEMS; HUMANS; MUCIN-1; NEOPLASM PROTEINS; NEOPLASMS; PROTEIN BINDING; RECEPTORS, CELL SURFACE;

EID: 77958152852     PISSN: 00052736     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamem.2010.02.004     Document Type: Review

References (112)

1. Ellington A.D., Szostak J.W. In vitro selection of RNA molecules that bind specific ligands. Nature 1990, 346:818-822.
2. Tuerk C., Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990, 249:505-510.
3. Padmanabhan K., Padmanabhan K.P., Ferrara J.D., Sadler J.E., Tulinsky A. The structure of alpha-thrombin inhibited by a 15-mer single-stranded DNA aptamer. J. Biol. Chem. 1993, 268:17651-17654.
4. Long S.B., Long M.B., White R.R., Sullenger B.A. Crystal structure of an RNA aptamer bound to thrombin. RNA 2008, 14:2504-2512.
5. Sheehan J.P., Sadler J.E. Molecular mapping of the heparin-binding exosite of thrombin. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:5518-5522.
6. Bode W., Turk D., Karshikov A. The refined 1.9-A X-ray crystal structure of D-Phe-Pro-Arg chloromethylketone-inhibited human alpha-thrombin: structure analysis, overall structure, electrostatic properties, detailed active-site geometry, and structure-function relationships. Protein Sci. 1992, 1:426-471.
7. Grosjean H., Benne R. Modification and Editing of RNA 1998, American Society for Microbiology, Washington DC.
8. Wakeman C.A., Winkler W.C., Dann C.E. Structural features of metabolite-sensing riboswitches. Trends Biochem. Sci. 2007, 32:415-424.
9. Chou S.H., Chin K.H., Wang A.H. Unusual DNA duplex and hairpin motifs. Nucleic Acids Res. 2003, 31:2461-2474.
10. Neidle S., Parkinson G.N. The structure of telomeric DNA. Curr. Opin. Struct. Biol. 2003, 13:275-283.
11. Siddiqui-Jain A., Grand C.L., Bearss D.J., Hurley L.H. Direct evidence for a G-quadruplex in a promoter region and its targeting with a small molecule to repress c-MYC transcription. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:11593-11598.
12. Phan A.T., Kuryavyi V., Ma J.B., Faure A., Andreola M.L., Patel D.J. An interlocked dimeric parallel-stranded DNA quadruplex: a potent inhibitor of HIV-1 integrase. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:634-639.
13. Teng Y., Girvan A.C., Casson L.K., Pierce W.M., Qian M., Thomas S.D., Bates P.J. AS1411 alters the localization of a complex containing protein arginine methyltransferase 5 and nucleolin. Cancer Res. 2007, 67:10491-10500.
14. Liu J., Cao Z., Lu Y. Functional nucleic acid sensors. Chem. Rev. 2009, 109:1948-1998.
15. Silverman S.K. Deoxyribozymes: selection design and serendipity in the development of DNA catalysts. Acc. Chem. Res. 2009, 42:1521-1531.
16. Chang S.S., Reuter V.E., Heston W.D., Bander N.H., Grauer L.S., Gaudin P.B. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. 1999, 59:3192-3198.
17. Ross J.S., Sheehan C.E., Fisher H.A., Kaufman R.P., Kaur P., Gray K., Webb I., Gray G.S., Mosher R., Kallakury B.V. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin. Cancer Res. 2003, 9:6357-6362.
18. Lupold S.E., Hicke B.J., Lin Y., Coffey D.S. Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res. 2002, 62:4029-4033.
19. Liu H., Rajasekaran A.K., Moy P., Xia Y., Kim S., Navarro V., Rahmati R., Bander N.H. Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res. 1998, 58:4055-4060.
20. Su S.L., Huang I.P., Fair W.R., Powell C.T., Heston W.D. Alternatively spliced variants of prostate-specific membrane antigen RNA: ratio of expression as a potential measurement of progression. Cancer Res. 1995, 55:1441-1443.
21. McNamara J.O., Andrechek E.R., Wang Y., Viles K.D., Rempel R.E., Gilboa E., Sullenger B.A., Giangrande P.H. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat. Biotechnol. 2006, 24:1005-1015.
22. Freeman S.D., Kelm S., Barber E.K., Crocker P.R. Characterization of CD33 as a new member of the sialoadhesin family of cellular interaction molecules. Blood 1995, 85:2005-2012.
23. Andrews R.G., Torok-Storb B., Bernstein I.D. Myeloid-associated differentiation antigens on stem cells and their progeny identified by monoclonal antibodies. Blood 1983, 62:124-132.
24. Andrews R.G., Takahashi M., Segal G.M., Powell J.S., Bernstein I.D., Singer J.W. The L4F3 antigen is expressed by unipotent and multipotent colony-forming cells but not by their precursors. Blood 1986, 68:1030-1035.
25. Griffin J.D., Linch D., Sabbath K., Larcom P., Schlossman S.F. A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells. Leuk. Res. 1984, 8:521-534.
26. Dinndorf P.A., Andrews R.G., Benjamin D., Ridgway D., Wolff L., Bernstein I.D. Expression of normal myeloid-associated antigens by acute leukemia cells. Blood 1986, 67:1048-1053.
27. Scheinberg D.A., Tanimoto M., McKenzie S., Strife A., Old L.J., Clarkson B.D. Monoclonal antibody M195: a diagnostic marker for acute myelogenous leukemia. Leukemia 1989, 3:440-445.
28. Terstappen L.W., Safford M., Konemann S., Loken M.R., Zurlutter K., Buchner T., Hiddemann W., Wormann B. Flow cytometric characterization of acute myeloid leukemia. Part II. Phenotypic heterogeneity at diagnosis. Leukemia 1992, 6:70-80.
29. Putti M.C., Rondelli R., Cocito M.G., Arico M., Sainati L., Conter V., Guglielmi C., Cantu-Rajnoldi A., Consolini R., Pession A., Zanesco L., Masera G., Biondi A., Basso G. Expression of myeloid markers lacks prognostic impact in children treated for acute lymphoblastic leukemia: Italian experience in AIEOP-ALL 88-91 studies. Blood 1998, 92:795-801.
30. Bernstein I.D. Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate. Leukemia 2000, 14:474-475.
31. Hamann P.R., Hinman L.M., Beyer C.F., Lindh D., Upeslacis J., Flowers D.A., Bernstein I. An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker. Bioconjug. Chem. 2002, 13:40-46.
32. van Der Velden V.H., te Marvelde J.G., Hoogeveen P.G., Bernstein I.D., Houtsmuller A.B., Berger M.S., van Dongen J.J. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood 2001, 97:3197-3204.
33. Walter R.B., Raden B.W., Kamikura D.M., Cooper J.A., Bernstein I.D. Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity. Blood 2005, 105:1295-1302.
34. Tsimberidou A.M., Giles F.J., Estey E., O'Brien S., Keating M.J., Kantarjian H.M. The role of gemtuzumab ozogamicin in acute leukaemia therapy. Br. J. Haematol. 2006, 132:398-409.
35. van der Velden V.H., Boeckx N., Jedema I., te Marvelde J.G., Hoogeveen P.G., Boogaerts M., van Dongen J.J. High CD33-antigen loads in peripheral blood limit the efficacy of gemtuzumab ozogamicin (Mylotarg) treatment in acute myeloid leukemia patients. Leukemia 2004, 18:983-988.
36. Chevallier P., Robillard N., Ayari S., Guillaume T., Delaunay J., Mechinaud F., Avet-Loiseau H., Mohty M., Harousseau J.L., Garand R. Persistence of CD33 expression at relapse in CD33(+) acute myeloid leukaemia patients after receiving Gemtuzumab in the course of the disease. Br. J. Haematol. 2008, 143:744-746.
37. Chen P., Wang J., Hope K., Jin L., Dick J., Cameron R., Brandwein J., Minden M., Reilly R.M. Nuclear localizing sequences promote nuclear translocation and enhance the radiotoxicity of the anti-CD33 monoclonal antibody HuM195 labeled with 111In in human myeloid leukemia cells. J. Nucl. Med. 2006, 47:827-836.
38. Gold P., Freedman S.O. Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J. Exp. Med. 1965, 121:439-462.
39. Hammarstrom S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin. Cancer Biol. 1999, 9:67-81.
40. Boucher D., Cournoyer D., Stanners C.P., Fuks A. Studies on the control of gene expression of the carcinoembryonic antigen family in human tissue. Cancer Res. 1989, 49:847-852.
41. Goldstein M.J., Mitchell E.P. Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer. Cancer Invest. 2005, 23:338-351.
42. Shih L.B., Goldenberg D.M., Xuan H., Lu H.W., Mattes M.J., Hall T.C. Internalization of an intact doxorubicin immunoconjugate. Cancer Immunol. Immunother. 1994, 38:92-98.
43. Ford C.H., Tsaltas G.C., Osborne P.A., Addetia K. Novel flow cytometric analysis of the progress and route of internalization of a monoclonal anti-carcinoembryonic antigen (CEA) antibody. Cytometry 1996, 23:228-240.
44. Stein R., Juweid M., Mattes M.J., Goldenberg D.M. Carcinoembryonic antigen as a target for radioimmunotherapy of human medullary thyroid carcinoma: antibody processing, targeting, and experimental therapy with 131I and 90Y labeled MAbs. Cancer Biother. Radiopharm. 1999, 14:37-47.
45. Schmidt M.M., Thurber G.M., Wittrup K.D. Kinetics of anti-carcinoembryonic antigen antibody internalization: effects of affinity, bivalency, and stability. Cancer Immunol. Immunother. 2008, 57:1879-1890.
46. Goldenberg D.M. Targeted therapy of cancer with radiolabeled antibodies. J. Nucl. Med. 2002, 43:693-713.
47. Behr T.M., Liersch T., Greiner-Bechert L., Griesinger F., Behe M., Markus P.M., Gratz S., Angerstein C., Brittinger G., Becker H., Goldenberg D.M., Becker W. Radioimmunotherapy of small-volume disease of metastatic colorectal cancer. Cancer 2002, 94:1373-1381.
48. Adams G.P., Schier R., McCall A.M., Simmons H.H., Horak E.M., Alpaugh R.K., Marks J.D., Weiner L.M. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res. 2001, 61:4750-4755.
49. Graff C.P., Wittrup K.D. Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention. Cancer Res. 2003, 63:1288-1296.
50. Robbins P.F., Kantor J.A., Salgaller M., Hand P.H., Fernsten P.D., Schlom J. Transduction and expression of the human carcinoembryonic antigen gene in a murine colon carcinoma cell line. Cancer Res. 1991, 51:3657-3662.
51. McGuckin M.A., Walsh M.D., Hohn B.G., Ward B.G., Wright R.G. Prognostic significance of MUC1 epithelial mucin expression in breast cancer. Hum. Pathol. 1995, 26:432-439.
52. Spicer A.P., Rowse G.J., Lidner T.K., Gendler S.J. Delayed mammary tumor progression in Muc-1 null mice. J. Biol. Chem. 1995, 270:30093-30101.
53. Taylor-Papadimitriou J., Burchell J., Miles D.W., Dalziel M. MUC1 and cancer. Biochim. Biophys. Acta 1999, 1455:301-313.
54. Hanisch F.G., Muller S. MUC1: the polymorphic appearance of a human mucin. Glycobiology 2000, 10:439-449.
55. Gendler S., Taylor-Papadimitriou J., Duhig T., Rothbard J., Burchell J. A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats. J. Biol. Chem. 1988, 263:12820-12823.
56. Hanisch F.G., Stadie T.R., Deutzmann F., Peter-Katalinic J. MUC1 glycoforms in breast cancer-cell line T47D as a model for carcinoma-associated alterations of 0-glycosylation. Eur. J. Biochem. 1996, 236:318-327.
57. Lloyd K.O., Burchell J., Kudryashov V., Yin B.W., Taylor-Papadimitriou J. Comparison of O-linked carbohydrate chains in MUC-1 mucin from normal breast epithelial cell lines and breast carcinoma cell lines. Demonstration of simpler and fewer glycan chains in tumor cells. J. Biol. Chem. 1996, 271:33325-33334.
58. Litvinov S.V., Hilkens J. The epithelial sialomucin, episialin, is sialylated during recycling. J. Biol. Chem. 1993, 268:21364-21371.
59. Ceriani R.L., Chan C.M., Baratta F.S., Ozzello L., DeRosa C.M., Habif D.V. Levels of expression of breast epithelial mucin detected by monoclonal antibody BrE-3 in breast-cancer prognosis. Int. J. Cancer 1992, 51:343-354.
60. Altschuler Y., Kinlough C.L., Poland P.A., Bruns J.B., Apodaca G., Weisz O.A., Hughey R.P. Clathrin-mediated endocytosis of MUC1 is modulated by its glycosylation state. Mol. Biol. Cell 2000, 11:819-831.
61. Henderikx P., Coolen-van Neer N., Jacobs A., van der Linden E., Arends J.W., Mullberg J., Hoogenboom H.R. A human immunoglobulin G1 antibody originating from an in vitro-selected Fab phage antibody binds avidly to tumor-associated MUC1 and is efficiently internalized. Am. J. Pathol. 2002, 160:1597-1608.
62. Ferreira C.S., Cheung M.C., Missailidis S., Bisland S., Gariepy J. Phototoxic aptamers selectively enter and kill epithelial cancer cells. Nucleic Acids Res. 2009, 37:866-876.
63. Huang Y.F., Shangguan D., Liu H., Phillips J.A., Zhang X., Chen Y., Tan W. Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells. Chembiochem 2009, 10:862-868.
64. Bagalkot V., Farokhzad O.C., Langer R., Jon S. An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform. Angew. Chem. Int. Ed. Engl. 2006, 45:8149-8152.
65. Willner D., Trail P.A., Hofstead S.J., King H.D., Lasch S.J., Braslawsky G.R., Greenfield R.S., Kaneko T., Firestone R.A. (6-Maleimidocaproyl)hydrazone of doxorubicin-a new derivative for the preparation of immunoconjugates of doxorubicin. Bioconjug. Chem. 1993, 4:521-527.
66. Goldmacher V.S., Scott C.F., Lambert J.M., McIntyre G.D., Blattler W.A., Collnhson A.R., Stewart J.K., Chong L.D., Cook S., Slayter H.S., et al. Cytotoxicity of gelonin and its conjugates with antibodies is determined by the extent of their endocytosis. J. Cell. Physiol. 1989, 141:222-234.
67. Chu T.C., Marks J.W., Lavery L.A., Faulkner S., Rosenblum M.G., Ellington A.D., Levy M. Aptamer:toxin conjugates that specifically target prostate tumor cells. Cancer Res. 2006, 66:5989-5992.
68. Hicke B.J., Stephens A.W., Gould T., Chang Y.F., Lynott C.K., Heil J., Borkowski S., Hilger C.S., Cook G., Warren S., Schmidt P.G. Tumor targeting by an aptamer. J. Nucl. Med. 2006, 47:668-678.
69. Hicke B.J., Marion C., Chang Y.F., Gould T., Lynott C.K., Parma D., Schmidt P.G., Warren S. Tenascin-C aptamers are generated using tumor cells and purified protein. J. Biol. Chem. 2001, 276:48644-48654.
70. Huang Y.F., Chang H.T., Tan W. Cancer cell targeting using multiple aptamers conjugated on nanorods. Anal. Chem. 2008, 80:567-572.
71. Chu T.C., Shieh F., Lavery L.A., Levy M., Richards-Kortum R., Korgel B.A., Ellington A.D. Labeling tumor cells with fluorescent nanocrystal-aptamer bioconjugates. Biosens. Bioelectron. 2006, 21:1859-1866.
72. Farokhzad O.C., Jon S., Khademhosseini A., Tran T.N., Lavan D.A., Langer R. Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res. 2004, 64:7668-7672.
73. Farokhzad O.C., Cheng J., Teply B.A., Sherifi I., Jon S., Kantoff P.W., Richie J.P., Langer R. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:6315-6320.
74. Zhang L., Radovic-Moreno A.F., Alexis F., Gu F.X., Basto P.A., Bagalkot V., Jon S., Langer R.S., Farokhzad O.C. Co-delivery of hydrophobic and hydrophilic drugs from nanoparticle-aptamer bioconjugates. Chem. Med. Chem. 2007, 2:1268-1271.
75. Dhar S., Gu F.X., Langer R., Farokhzad O.C., Lippard S.J. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:17356-17361.
76. Bagalkot V., Zhang L., Levy-Nissenbaum E., Jon S., Kantoff P.W., Langer R., Farokhzad O.C. Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. Nano Lett. 2007, 7:3065-3070.
77. Kaneda Y. Virosomes: evolution of the liposome as a targeted drug delivery system. Adv. Drug Deliv. Rev. 2000, 43:197-205.
78. Wagner A., Platzgummer M., Kreismayr G., Quendler H., Stiegler G., Ferko B., Vecera G., Vorauer-Uhl K., Katinger H. GMP production of liposomes-a new industrial approach. J. Liposome Res. 2006, 16:311-319.
79. Willis M.C., Collins B.D., Zhang T., Green L.S., Sebesta D.P., Bell C., Kellogg E., Gill S.C., Magallanez A., Knauer S., Bendele R.A., Gill P.S., Janjic N. Liposome-anchored vascular endothelial growth factor aptamers. Bioconjug. Chem. 1998, 9:573-582.
80. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986, 46:6387-6392.
81. Mamot C., Drummond D.C., Greiser U., Hong K., Kirpotin D.B., Marks J.D., Park J.W. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. Cancer Res. 2003, 63:3154-3161.
82. Woo J., Chiu G.N., Karlsson G., Wasan E., Ickenstein L., Edwards K., Bally M.B. Use of a passive equilibration methodology to encapsulate cisplatin into preformed thermosensitive liposomes. Int. J. Pharm. 2008, 349:38-46.
83. Bock L.C., Griffin L.C., Latham J.A., Vermaas E.H., Toole J.J. Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature 1992, 355:564-566.
84. Stribling W.K., Slaughter T.F., Houle T.T., Sane D.C. Beyond the platelet count: heparin antibodies as independent risk predictors. Am. Heart J. 2007, 153:900-906.
85. Schneider D.J., Feigon J., Hostomsky Z., Gold L. High-affinity ssDNA inhibitors of the reverse transcriptase of type 1 human immunodeficiency virus. Biochemistry 1995, 34:9599-9610.
86. Chou S.H., Chin K.H., Wang A.H. DNA aptamers as potential anti-HIV agents. Trends Biochem. Sci. 2005, 30:231-234.
87. Zhou J., Swiderski P., Li H., Zhang J., Neff C.P., Akkina R., Rossi J.J. Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells. Nucleic Acids Res. 2009, 37:3094-3109.
88. Ng E.W., Shima D.T., Calias P., Cunningham E.T., Guyer D.R., Adamis A.P. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat. Rev. Drug Discov. 2006, 5:123-132.
89. Kourlas H., Abrams P. Ranibizumab for the treatment of neovascular age-related macular degeneration: a review. Clin. Ther. 2007, 29:1850-1861.
90. Conrad R., Keranen L.M., Ellington A.D., Newton A.C. Isozyme-specific inhibition of protein kinase C by RNA aptamers. J. Biol. Chem. 1994, 269:32051-32054.
91. Schneider D.J., Feigon J., Hostomsky Z., Gold L. High-affinity ssDNA inhibitors of the reverse transcriptase of type 1 human immunodeficiency virus. Biochemistry 1995, 34:9599-9610.
92. White R.R., Sullenger B.A., Rusconi C.P. Developing aptamers into therapeutics. J. Clin. Invest. 2000, 106:929-934.
93. Wagner H. The immunobiology of the TLR9 subfamily. Trends Immunol. 2004, 25:381-386.
94. Healy J.M., Lewis S.D., Kurz M., Boomer R.M., Thompson K.M., Wilson C., McCauley T.G. Pharmacokinetics and biodistribution of novel aptamer compositions. Pharm. Res. 2004, 21:2234-2246.
95. Peng C.G., Damha M.J. G-quadruplex induced stabilization by 2'-deoxy-2'-fluoro-d-arabinonucleic acids. Nucleic Acids Res. 2007, 35:4977-4988.
96. Aurup H., Williams D.M., Eckstein F. 2'-Fluoro- and 2'-amino-2'-deoxynucleoside 5'-triphosphates as substrates for T7 RNA polymerase. Biochemistry 1992, 31:9636-9641.
97. Latham J.A., Johnson R., Toole J.J. The application of a modified nucleotide in aptamer selection: novel thrombin aptamers containing 5-(1-pentynyl)-2'-deoxyuridine. Nucleic Acids Res. 1994, 22:2817-2822.
98. Padilla R., Sousa R. Efficient synthesis of nucleic acids heavily modified with non-canonical ribose 2'-groups using a mutantT7 RNA polymerase. Nucleic Acids Res. 1999, 27:1561-1563.
99. Jellinek D., Green L.S., Bell C., Lynott C.K., Gill N., Vargeese C., Kirschenheuter G., McGee D.P., Abesinghe P., Pieken W.A., et al. Potent 2'-amino-2'-deoxypyrimidine RNA inhibitors of basic fibroblast growth factor. Biochemistry 1995, 34:11363-11372.
100. Schoetzau T., Langner J., Moyroud E., Roehl I., Vonhoff S., Klussmann S. Aminomodified nucleobases: functionalized nucleoside triphosphates applicable for SELEX. Bioconjug. Chem. 2003, 14:919-926.
101. Eaton B.E., Gold L., Hicke B.J., Janjic N., Jucker F.M., Sebesta D.P., Tarasow T.M., Willis M.C., Zichi D.A. Post-SELEX combinatorial optimization of aptamers. Bioorg. Med. Chem. 1997, 5:1087-1096.
102. Barciszewski J., Medgaard M., Koch T., Kurreck J., Erdmann V.A. Locked nucleic acid aptamers. Methods Mol. Biol. 2009, 535:165-186.
103. Vester B., Wengel J. LNA (locked nucleic acid): high-affinity targeting of complementary RNA and DNA. Biochemistry 2004, 43:13233-13241.
104. Santulli-Marotto S., Nair S.K., Rusconi C., Sullenger B., Gilboa E. Multivalent RNA aptamers that inhibit CTLA-4 and enhance tumor immunity. Cancer Res. 2003, 63:7483-7489.
105. McNamara J.O., Kolonias D., Pastor F., Mittler R.S., Chen L., Giangrande P.H., Sullenger B., Gilboa E. Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in mice. J. Clin. Invest. 2008, 118:376-386.
106. Bates P.J., Kahlon J.B., Thomas S.D., Trent J.O., Miller D.M. Antiproliferative activity of G-rich oligonucleotides correlates with protein binding. J. Biol. Chem. 1999, 274:26369-26377.
107. Girvan A.C., Teng Y., Casson L.K., Thomas S.D., Juliger S., Ball M.W., Klein J.B., Pierce W.M., Barve S.S., Bates P.J. AGRO100 inhibits activation of nuclear factor-kappaB (NF-kappaB) by forming a complex with NF-kappaB essential modulator (NEMO) and nucleolin. Mol. Cancer Ther. 2006, 5:1790-1799.
108. Dapic V., Bates P.J., Trent J.O., Rodger A., Thomas S.D., Miller D.M. Antiproliferative activity of G-quartet-forming oligonucleotides with backbone and sugar modifications. Biochemistry 2002, 41:3676-3685.
109. Tong G.J., Hsiao S.C., Carrico Z.M., Francis M.B. Viral capsid DNA aptamer conjugates as multivalent cell-targeting vehicles. J. Am. Chem. Soc. 2009, 131:11174-11178.
110. Cheng J., Teply B.A., Sherifi I., Sung J., Luther G., Gu F.X., Levy-Nissenbaum E., Radovic-Moreno A.F., Langer R., Farokhzad O.C. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials 2007, 28:869-876.
111. Cao Z., Tong R., Mishra A., Xu W., Wong G.C., Cheng J., Lu Y. Reversible cell-specific drug delivery with aptamer-functionalized liposomes. Angew. Chem. Int. Ed. Engl. 2009, 48:6494-6498.
112. Chu T.C., Shieh F., Lavery L.A., Levy M., Richards-Kortum R., Korgel B.A., Ellington A.D. Labeling tumor cells with fluorescent nanocrystal-aptamer bioconjugates. Biosensors & Bioelectronics 2006, 21:1859-1866.